- Tytuł:
- 32O 5-year (y) overall survival (OS) with maintenance olaparib (ola) plus bevacizumab (bev) by clinical risk in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial
- Autorzy:
- Źródło:
- In ESMO Open February 2023 8(1) Supplement 1
Czasopismo naukowe